Ascletis Reports First Patient Dosing in the P-II Clinical Trial of ASC41 for Liver Biopsy-Proven Non-Alcoholic Steatohepatitis
Shots:
- The first patient has been dosed in the 52wk. P-II trial to evaluate the safety & efficacy of ASC41 (2/4mg, qd) vs PBO in a ratio (1:1:1) in 180 patients with liver biopsy-proven NASH. The patient’s enrollment is expected to be completed in Q3’23
- The 1EPs of the trial are NAFLD activity score improvement ≥2 points (improvement in inflammation or ballooning) & no worsening of fibrosis
- In the P-I trial of 65 patients with elevated LDL-C (>110 mg/dL), ASC41 showed a reduction in LDL-C and TG over PBO after 14 days of treatment, the relative TG reduction from baseline was 39% at a very low dose of 1mg. The therapy showed higher potency & requires a lower dosage (1mg) with 30% relative TG reduction over MGL-3196
Ref: PRNewswire | Image: Ascletis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
